{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:47:50Z","timestamp":1780494470223,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jfma.2025.11.011","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T23:40:07Z","timestamp":1763336407000},"page":"S109-S112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S2","title":["Hepatitis C micro-elimination in people who inject drugs: Incarcerated or methadone maintenance therapy in Taiwan"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-3761","authenticated-orcid":false,"given":"Chien-Hung","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.11.011_bib1","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1093\/infdis\/jiad016","article-title":"Policy and strategy for hepatitis C virus elimination at the national level: experience in Taiwan","volume":"228","author":"Chien","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.11.011_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro-elimination - a path to global elimination of hepatitis C","volume":"67","author":"Lazarus","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.11.011_bib3","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.jfma.2025.11.011_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.jfma.2025.11.011_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001625","article-title":"Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts","volume":"11","author":"Huang","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.jfma.2025.11.011_bib6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.addbeh.2013.01.010","article-title":"High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan","volume":"38","author":"Ng","year":"2013","journal-title":"Addict Behav"},{"key":"10.1016\/j.jfma.2025.11.011_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/JCMA.0000000000000312","article-title":"Risk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy","volume":"83","author":"Wang","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jfma.2025.11.011_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/v14081637","article-title":"Collaborative referral model to achieve hepatitis C micro-elimination in methadone maintenance treatment patients during the COVID-19 pandemic","volume":"14","author":"Tai","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2025.11.011_bib9","article-title":"Microelimination of chronic hepatitis C by universal screening plus direct-acting antivirals for incarcerated persons in Taiwan","volume":"7","author":"Yang","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2025.11.011_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3748\/wjg.v28.i2.263","article-title":"Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison","volume":"28","author":"Chen","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.11.011_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/3184892","article-title":"The efficacy of On-Site integration screening and microelimination programs for chronic hepatitis C in a detection center: a comparison of the treatment outcomes and characteristics of incarcerated patients and outpatients","volume":"2024","author":"Chang","year":"2024","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.jfma.2025.11.011_bib12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jiph.2023.05.019","article-title":"A new collaborative care approach toward hepatitis C elimination in marginalized populations","volume":"16","author":"Su","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jfma.2025.11.011_bib13","article-title":"Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection","volume":"13","author":"Cheng","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.11.011_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070490","article-title":"Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis","volume":"13","author":"Tsai","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfma.2025.11.011_bib15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1186\/s12889-022-14623-6","article-title":"Hepatitis C prevalence in incarcerated settings between 2013-2021: a systematic review and meta-analysis","volume":"22","author":"Busschots","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jfma.2025.11.011_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2025.11.011_bib17","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.3201\/eid3013.230859","article-title":"Advancing hepatitis C elimination through opt-out universal screening and treatment in carceral settings, United States","volume":"30","author":"McNamara","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jfma.2025.11.011_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/CLD.0000000000000117","article-title":"The hepatitis C care cascade in California state prisons: screening and treatment scale-up and progress toward elimination, 2016-2023","volume":"23","author":"Lucas","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2025.11.011_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5694\/mja2.51854","article-title":"Consensus recommendations on the management of hepatitis C in Australia's prisons","volume":"218","author":"Winter","year":"2023","journal-title":"Med J Aust"},{"key":"10.1016\/j.jfma.2025.11.011_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/cid\/ciae471","article-title":"Long-term outcomes of a decentralized, nurse-led, statewide model of care for hepatitis C among people in prison in Victoria, Australia","volume":"80","author":"MacIsaac","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2025.11.011_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104658","article-title":"Opioid agonist treatment programs and hepatitis C virus elimination in Taiwan: ways of expanding the care cascade in screening and treatment","volume":"134","author":"Chung","year":"2024","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jfma.2025.11.011_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/kjm2.12086","article-title":"Integrated care for methadone maintenance patients with hepatitis C virus infection","volume":"35","author":"Tai","year":"2019","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.11.011_bib23","article-title":"Comparison of the efficacies of direct-acting antiviral treatment for HCV infection in people who inject drugs and non-drug users","volume":"58","author":"Hsu","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jfma.2025.11.011_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa310","article-title":"Optimizing hepatitis C virus (HCV) treatment in a US colocated HCV\/opioid agonist therapy program","volume":"7","author":"Habchi","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2025.11.011_bib25","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2024.2452","article-title":"Integrated hepatitis C-Opioid use disorder care through facilitated telemedicine: a randomized trial","volume":"331","author":"Talal","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2025.11.011_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/kjm2.12788","article-title":"Hepatitis C virus micro-elimination in people who inject drugs: challenges and chance in Taiwan and worldwide","volume":"40","author":"Tai","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.11.011_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2025.10.020","article-title":"Changhua integrated program to stop HCV infection (CHIPS-C): a county-wide model for integrated HCV elimination in Taiwan","author":"Yang","year":"2025","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.11.011_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2025.09.031","article-title":"Current status of HCV elimination in Taiwan","author":"Chien","year":"2025","journal-title":"J Formos Med Assoc"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462500600X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462500600X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:58:37Z","timestamp":1766159917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966462500600X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"alternative-id":["S092966462500600X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.11.011","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C micro-elimination in people who inject drugs: Incarcerated or methadone maintenance therapy in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}